Oxford BioDynamics Plc is a biotechnology company with a proprietary biomarker discovery platform, EpiSwitch™, based on the latest advances in gene expression, non-coding RNA and epigenetics. EpiSwitch™ is a proprietary industrial platform for the discovery, evaluation, validation and monitoring of a novel class of epigenetic biomarkers known as ‘chromosome conformation signatures’. The company's proprietary technology platform enables pharmaceutical companies to accelerate and improve the rate of drug discovery and development.